Population based case-control study of sick leave in postmenopausal women before diagnosis of hyperparathyroidism

Objective: To analyse sick leave in women at risk of primary hyperparathyroidism before its diagnosis.

Cumplimiento de las recomendaciones de aportes de vitamina D y calcio en pacientes con osteoporosis

Objetivos: - Conocer los aportes diarios de vitamina D y calcio (suplementos farmacológicos y dieta) en mujeres mayores de 65 años. - Conocer si existe relación entre el consumo diario de vitamina D y las variables clínicas y sociodemográficas.

A peculiar and unusual disease of the osseous tissue in the horse : resembling, in many of its characteristics, Mollities ossium, Rhachitis, Osteoporosis, and fatty degeneration of bone /

"Reprinted from the 'Veterinarian'."

Osteoporosis and hip fractures : 1995-2000 /

Hip fracture is the most adverse outcome of osteoporosis. Few surveillance sources exist to estimate the extent of the burden of illness of osteoporosis in Illinois. Because hip fractures are an important proxy measure for the existence of osteoporosis, the Illinois Health Care Cost Containment Council examined hospital use, treatment and outcome measures for hip fracture patients during the years 1995 through 2000. Osteoporosis, as the underlying cause of hip fracture hospitalizations, is investigated for results of treatment and disposition at discharge. In the year 1995, 12,637, discharges for hip fracture patients were reported by Illinois hospitals. In contrast, in the year 2000, 12,311, discharges for hip fracture patients were reported by Illinois hospitals. This study will provide a descriptive analysis of hospital reported discharges during this six-year period, focusing on patient age and gender, cause of injury, treatments, outcomes, billed charges and expected payment source. A significant percentage of hip fractures occurred in people aged 65 and above. Hip fracture rates per thousand persons in females exceeded males in every age group in the study. Females accounted for approximately 75% of all hip fracture discharges during the study period. Facility charges for hip fracture cases in 1995 were over $213.5 million. Comparable charges in 2000 exceeded $270 million. Over 80% of patients in 2000 were discharged to another health care facility for additional care. A review of pathological fractures and reported cases of diagnosed osteoporosis are included to round out the study.

Osteoporosis in Illinois : analysis of hospital discharge records from 1992 to 1995 /

"December 1997. "

Osteoporosis in Illinois, 2003.

"3/03"--Colophon.

The effect of hormone replacement therapy and/or exercise on skeletal muscle attenuation in postmenopausal women: a yearlong intervention

Hormone replacement therapy (HRT) has been reported to exert a positive effect on preserving muscle strength following the menopause, however, the mechanism of action remains unclear. We examined whether the mechanism involved preservation of muscle composition as determined by skeletal muscle attenuation. Eighty women aged 50-57 years were randomly assigned to either: HRT, exercise (Ex), HRT + exercise (ExHRT), and control (Co) for 1 year. The study was double-blinded with subjects receiving oestradiol and norethisterone acetate (Kliogest) or placebo. Exercise included progressive high-impact training for the lower limbs. Skeletal muscle attenuation in Hounsfield units (HU) was determined by computed tomography of the mid-thigh. Areas examined were the quadriceps compartment (includes intermuscular adipose tissue), quadriceps muscles, the posterior compartment and posterior muscles. Muscle performance was determined by knee extensor strength, vertical jump height, and running speed over 20 m. Fifty-one women completed the intervention. Vertical jump height and running speed improved in the HRT and ExHRT groups compared with Co (interaction, P < 0.01). For both the quadriceps compartment and quadriceps muscles, HU significantly increased (interaction, P <= 0.005) for HRT, Ex, and ExHRT compared with Co. For the posterior compartment, HU for the HRT and ExHRT were significantly increased compared with Co, while for posterior muscles, ExHRT was significantly greater than Co. Although the effects were modest, the results indicate that HRT, either alone or combined with exercise, may play a role in preserving/improving skeletal muscle attenuation in early postmenopausal women and thereby exert a positive effect on muscle performance.

Volumetric and areal bone mineral density measures are associated with cardiovascular disease in older men and women: The health, aging, and body composition study

The associations of volumetric (vBMD) and areal (aBMD) bone mineral density measures with prevalent cardiovascular disease (CVD) and subclinical peripheral arterial disease (PAD) were investigated in a cohort of older men and women enrolled in the Health, Aging, and Body Composition Study. Participants were 3,075 well-functioning white and black men and women (42% black, 51% women), aged 68-80 years. Total hip, femoral neck, and trochanter aBMD were measured using dual-energy X-ray absorptiometry. Quantitative computed tomography was used to evaluate spine trabecular, integral, and cortical vBMD measures in a subgroup (n = 1,489). Logistic regression was performed to examine associations of BMD measures with CVD and PAD. The prevalence of CVD (defined by coronary heart disease, PAD, cerebrovascular disease, or congestive heart failure) was 29.8%. Among participants without CVD, 10% had subclinical PAD (defined as ankle-arm index < 0.9). Spine vBMD measures were inversely associated with CVD in men (odds ratio of integral [ORintegral] = 1.34, 95% confidence interval [CI] 1.10-1.63; ORtrabecular = 1.25, 95% CI 1.02-1.53; ORcortical = 1.36, 95% CI 1.11-1.65). In women, for each standard deviation decrease in integral vBMD, cortical vBMD, or trochanter aBMD, the odds of CVD were significantly increased by 28%, 27%, and 22%, respectively. Total hip aBMD was associated with subclinical PAD in men (OR = 1.39, 95% CI 1.03-1.84) but not in women. All associations were independent of age and shared risk factors between BMD and CVD and were not influenced by inflammatory cytokines (interleukin-6 and tumor necrosis factors-alpha). In conclusion, our results provide further evidence for an inverse association between BMD and CVD in men and women. Future research should investigate common pathophysiological links for osteoporosis and CVD.

Conditional deletion of hypothalamic Y2 receptors reverts gonadectomy-induced bone loss in adult mice

Reduction in levels of sex hormones at menopause in women is associated with two common, major outcomes, the accumulation of white adipose tissue, and the progressive loss of bone because of excess osteoclastic bone resorption exceeding osteoblastic bone formation. Current antiresorptive therapies can reduce osteoclastic activity but have only limited capacity to stimulate osteoblastic bone formation and restore lost skeletal mass. Likewise, the availability of effective pharmacological weight loss treatments is currently limited. Here we demonstrate that conditional deletion of hypothalamic neuropeptide Y2 receptors can prevent ongoing bone loss in sex hormone-deficient adult male and female mice. This benefit is attributable solely to activation of an anabolic osteoblastic bone formation response that counterbalances persistent elevation of bone resorption, suggesting the Y2-mediated anabolic pathway to be independent of sex hormones. Furthermore, the increase in fat mass that typically occurs after ovariectomy is prevented by germ line deletion of Y2 receptors, whereas in male mice body weight and fat mass were consistently lower than wild-type regardless of sex hormone status. Therefore, this study indicates a role for Y2 receptors in the accumulation of adipose tissue in the hypogonadal state and demonstrates that hypothalamic Y2 receptors constitutively restrain osteoblastic activity even in the absence of sex hormones. The increase in bone formation after release of this tonic inhibition suggests a promising new avenue for osteoporosis treatment.